Novartis Ag (NVS) Net Cash Flow (2009 - 2026)

Novartis Ag has disclosed Net Cash Flow across 18 years of filings, most recently posting $757.0 million for Q2 2026.

• In Q2 2026, Net Cash Flow rose 195.58% year-over-year to $757.0 million; the TTM figure through Jun 2026 stood at -$6.4 billion (down 637.9% YoY), while the FY2025 annual figure was -$600.0 million, down 102.28% from the prior year.
• Net Cash Flow came in at $757.0 million for Q2 2026 at Novartis Ag, up from -$4.5 billion in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $21.7 billion in Q4 2023 to a low of -$10.2 billion in Q2 2022.
• Average Net Cash Flow over 5 years is $2.0 billion, with a median of -$17.5 million recorded in 2025.
• The largest YoY upside for Net Cash Flow was 219.73% in 2022 against a maximum downside of 869.09% in 2022.
• Over 5 years, Net Cash Flow stood at $16.6 billion in 2022, then jumped by 30.44% to $21.7 billion in 2023, then plunged by 124.6% to -$5.3 billion in 2024, then retreated by 4.24% to -$5.6 billion in 2025, then jumped by 113.62% to $757.0 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $757.0 million in Q2 2026, -$4.5 billion in Q1 2026, and -$5.6 billion in Q4 2025.